Medscape

FDA Asks for Drug Interaction Studies on Kayexalate

The US Food and Drug Administration (FDA) has asked the maker of sodium polystyrene sulfonate (Kayexalate), Concordia Pharmaceuticals, to conduct studies of the drug's potential to interact with other ...
Monthly Prescribing Reference

New Drug Approval Leads FDA to Issue Alert for Similar Products

The Food and Drug Administration (FDA) announced that it will require the manufacturer of Kayexalate (sodium polystyrene sulfonate; Concordia Pharmaceuticals) to conduct studies on drug-drug ...
Nature

Necrotizing enterocolitis in a 850 gram infant receiving sorbitol-free sodium polystyrene sulfonate (Kayexalate): clinical and histopathologic findings

We have presented a case of NEC in a preterm infant affected by severe hyperkalemia and treated with SPS not suspended in sorbitol. SPS is a cation-exchange resin, which may be administered either ...
FiercePharma

Bourne Partners and Cerberus Capital Portfolio Company, Covis Pharma, Acquires US Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate®

Bourne Partners and Cerberus Capital Portfolio Company, Covis Pharma, Acquires US Rights from Sanofi for Nilandron®, Plaquenil®, Rilutek®, Uroxatral®, and Kayexalate® ZUG Switzerland (April 4, 2013) - ...
Monthly Prescribing Reference

Colonic Ulceration in a Patient with Renal Disease and Hyperkalemia

SPS-induced bowel injury requires confirmation of crystals on microscopy, which distinguishes it from other causes of ischemic colitis. SPS crystals are typically polygonal in shape, basophilic, and ...